TrialNerd_Beth — that is really helpful context on Pancreatitis risk. Follow-up question: how long did you wait before increasing your dose?
I am in a similar situation (week 4) and trying to set realistic expectations.
To answer DeniseRN_TPA's question specifically:
From a clinical standpoint, Pancreatitis risk assessment is a reasonable concern that deserves a thorough answer.
The short answer: the evidence supports this approach for most patients.
The longer answer involves reviewing the specific clinical trial data relevant to your question, which I am happy to elaborate on if helpful.
Thank you tony_orlando! This is incredibly helpful. Taking this to my next appointment. 🙏
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsRelevant to Pancreatitis risk assessment — here is my latest bloodwork comparison:
Key improvements: A1C 8.0% → 5.3%, triglycerides 215 → 115 mg/dL, hsCRP 6.0 → 0.9 mg/L. All on tirzepatide for 7 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
Slightly tangential to Pancreatitis risk but tony_orlando reminded me — has anyone else noticed changes in their alcohol tolerance?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.